Glenmark, InvaGen ink deal

Glenmark Pharmaceuticals wholly owned US subsidiary, Glenmark Pharmaceuticals, has made a exclusive marketing tie-up with InvaGen for its Fosinopril Sodium oral tablets (Monopril) in the US market.

According to a release issued by Glenmark Pharmaceuticals to the Bombay Stock Exchange, InvaGen filed the ANDA and obtained USFDA nod for the Fosinopril Sodium product in April 2005.

Fosinopril is an anti-hypertensive agent of the ACE Inhibitor class, with a US generic market size of $92

million, which is used to lower blood pressure and treat congestive heart failure.

Glenn Saldanha, MD and CEO of Glen Pharma stated, "This agreement is in line with our strategy to partner with local US manufacturers to accelerate establishing our presence as a major player in the US market."